Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 13 de 13
Arch. argent. pediatr ; 118(1): e8-e15, 2020-02-00. tab, ilus
Article in English, Spanish | LILACS, BINACIS | ID: biblio-1095409


Introducción. Los probióticos y prebióticos presentan beneficios potenciales en la inflamacióncrónica de las mucosas, incluida la prevención de la enterocolitis necrosante. No obstante, los mecanismos y resultados de estos efectos inmunomoduladores son confusos. El objetivo fue investigar la respuesta de las citocinas a Lactobacillus y Bifidobacterium asociados con fructo- y galactooligosacáridos (simbióticos) y lactoferrina en recién nacidos de muy bajo peso al nacer.Población y métodos. Se asignó aleatoriamente a lactantes con ≤32 semanas de gestación y ≤1500 g de peso para recibir simbióticos o 1 ml de agua destilada como placebo desde la primera alimentación hasta el alta. Se obtuvieron muestras de sangre los días posnatales 0 ± 2, 14 ± 2 y 28 ± 2, y se midieron interferón-γ, interleucina (IL)-5, IL-10 e IL-17A.Resultados. En el grupo del estudio (n = 25), la concentración de IL-10 disminuyó a lo largo del estudio (p = 0,011), pero no cambió en el grupo de referencia. La concentración de IL-5 se mantuvo constante los primeros 14 días y luego disminuyó significativamente (p= 0,042) en el grupo del estudio, mientras que aumentó en los primeros 14 días (p = 0,019) y luego disminuyó en 28 días (p = 0,011) en el grupo de referencia (n = 25).La concentración de otras citocinas no cambió a lo largo del estudio.Conclusión. El uso combinado de probióticos con oligosacáridos y lactoferrina estuvo asociado con una disminución en la concentración de IL-10, pero no se observó un cambio en las otras citocinas.

Introduction. Probiotics and prebiotics, which are multifunctional agents, have potential benefits in chronic mucosal inflammation, including the prevention of necrotizing enterocolitis. However, the mechanisms and the results of these immunomodulatory effects are not clear. This study aimed to investigate the cytokine response to the combination of Lactobacillus and Bifidobacterium together with fructo- and galacto-oligosaccharides (symbiotic) and lactoferrin in very low birth weight neonates.Population and Methods. Infants ≤ 32 GWs and ≤ 1,500 g were randomly assigned to receive a symbiotic combination or 1 ml distilled water as placebo starting with the first feed until discharge. Blood samples were obtained at postnatal 0 ± 2, 14 ± 2, and 28 ± 2 days, and the serum levels of interferon-γ, interleukin (IL)-5, IL-10, and IL-17A were measured.Results. In the study group (n = 25), the IL-10 levels decreased throughout the study period (p = 0.011) but did not change in the control group. The IL-5 levels remained steady in the first 14 days and decreased significantly thereafter (p = 0.042) in the study group, whereas they increased in the first 14 days (p = 0.019), and then decreased in 28 days (p = 0.011) in the control group (n = 25). The levels of the other cytokines did not change throughout the study period.Conclusion.The combined use of probiotics with oligosaccharides and lactoferrin was associated with a decrease in IL-10 levels, but no change was observed in the other cytokines.

Humans , Male , Female , Infant, Newborn , Cytokines/analysis , Probiotics/therapeutic use , Prebiotics , Synbiotics/administration & dosage , Lactoferrin/administration & dosage , Oligosaccharides/therapeutic use , Turkey , Prospective Studies , Cytokines/blood , Infant, Very Low Birth Weight , Enterocolitis, Necrotizing/prevention & control , Milk, Human
J. pediatr. (Rio J.) ; 95(6): 642-656, Nov.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1056660


ABSTRACT Objective: This narrative review aimed to provide practitioners a synthesis of the current knowledge on the role of a low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet in reducing symptoms associated with functional abdominal pain disorders in children. This review is focused on the pathophysiology, efficacy and criticism of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet in children. Sources: Cochrane Database, Pubmed and Embase were searched using specific terms for Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet interventions and functional abdominal pain disorders. Summary of the findings: In children, only one Randomized Control Trial and one open-label study reported positive results of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols diet; one Randomized Control Trial showed exacerbation of symptoms with fructans in children with Irritable Bowel Syndrome; no effect was found for the lactose-free diet whilst fructose-restricted diets were effective in 5/6 studies. Conclusions: In children there are few trials evaluating low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols in functional abdominal pain disorders, with encouraging data on the therapeutic efficacy particularly of fructose-restricted diet. Additional efforts are still needed to fill this research gap and clarify the most efficient way for tailoring dietary restrictions based on the patient's tolerance and/or identification of potential biomarkers of low Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols efficacy, to maintain nutritional adequacy and to simplify the adherence to diet by labeling Fermentable Oligosaccharides Disaccharides Monosaccharides and Polyols content in commercial products.

RESUMO Objetivo: Nos últimos anos, foram feitos esforços consideráveis para esclarecer o papel da dieta com baixo teor de oligossacarídeos fermentáveis, dissacarídeos, monossacarídeos e polióis (FODMAPs) para o tratamento de distúrbios gastrintestinais funcionais (DGIFs). Esta revisão narrativa teve como objetivo fornecer aos profissionais uma síntese do conhecimento atual sobre o papel de uma dieta com baixo teor de FODMAPs (BFM) na redução dos sintomas associados a distúrbios funcionais de dor abdominal (DFDA) em crianças. Esta revisão está focada na fisiopatologia, eficácia e crítica da dieta BFM em crianças. Fontes: O banco de dados Cochrane, Pubmed e Embase foram pesquisados com o uso dos termos específicos para intervenções na dieta FODMAP e DFDA. Resumo dos achados: Em crianças, apenas um estudo controlado randomizado e um estudo aberto relataram resultados positivos da dieta BFM; um estudo controlado randomizado mostrou exacerbação dos sintomas com frutanos em crianças com síndrome do intestino irritável; nenhum efeito foi encontrado para a dieta livre de lactose, enquanto dietas com restrição de frutose foram eficazes em 5/6 estudos. Conclusões: Existem poucos estudos que avaliam BFM em DFDA em crianças, com dados encorajadores sobre a eficácia terapêutica, particularmente de dietas com restrição de frutose. Esforços adicionais ainda são necessários para preencher essa lacuna de pesquisa e esclarecer a maneira mais eficiente de adaptar as restrições dietéticas com base na tolerância do paciente e/ou identificação de biomarcadores potenciais de eficácia da BFM, para manter a adequação nutricional e simplificar a adesão à dieta, ao incluir informações sobre conteúdo de FODMAPs em rótulos de produtos comerciais.

Humans , Abdominal Pain/diet therapy , Diet, Carbohydrate-Restricted , Oligosaccharides/metabolism , Oligosaccharides/therapeutic use , Irritable Bowel Syndrome , Diet , Disaccharides/metabolism , Disaccharides/therapeutic use , Monosaccharides/metabolism , Monosaccharides/therapeutic use
Acta cir. bras ; 30(5): 366-370, 05/2015.
Article in English | LILACS | ID: lil-747027


PURPOSE: To address the effects of fructooligosaccharides (FOS) intake on serum cholesterol levels. METHODS: We performed a search for scientific articles in MEDLINE database from 1987 to 2014, using the following English keywords: fructooligosaccharides; fructooligosaccharides and cholesterol. A total of 493 articles were found. After careful selection and exclusion of duplicate articles 34 references were selected. Revised texts were divided into two topics: "FOS Metabolism" and "FOS effects on plasma cholesterol." RESULTS: The use of a FOS diet prevented some lipid disorders and lowered fatty acid synthase activity in the liver in insulin-resistant rats. There was also reduction in weight and total cholesterol in beagle dogs on a calorie-restricted diet enriched with short-chain FOS. Another study found that 2g FOS daily consumption increased significantly serum HDL cholesterol levels but did not ensure a significant reduction in levels of total cholesterol and triglycerides.. Patients with mild hypercholesterolemia receiving short-chain FOS 10.6g daily presented no statistically significant reduction in serum cholesterol levels. However, when FOS was offered to patients that changed their lifestyle, the reduction of LDL cholesterol and steatosis was higher. CONCLUSIONS: Fructooligosaccharides intake may have a beneficial effect on lipid metabolism and regulation of serum cholesterol levels in individuals that change their lifestyle. FOS supplementation use in diets may therefore be a strategy for lowering cholesterol. .

Animals , Dogs , Humans , Rats , Cholesterol/blood , Oligosaccharides/therapeutic use , Dietary Supplements , Dyslipidemias/drug therapy , Lipid Metabolism/drug effects , Oligosaccharides/metabolism , Oligosaccharides/pharmacology , Reproducibility of Results , Treatment Outcome
Indian J Exp Biol ; 2015 Mar; 53(3): 131-142
Article in English | IMSEAR | ID: sea-158396


Oligosaccharides and dietary fibres are non-digestible food ingredients that preferentially stimulate the growth of prebiotic Bifidobacterium and other lactic acid bacteria in the gastro-intestinal tract. Xylooligosaccharides (XOS) provide a plethora of health benefits and can be incorporated into several functional foods. In the recent times, there has been an over emphasis on the microbial conversion of agroresidues into various value added products. Xylan, the major hemicellulosic component of lignocellulosic materials (LCMs), represents an important structural component of plant biomass in agricultural residues and could be a potent bioresource for XOS. On an industrial scale, XOS can be produced by chemical, enzymatic or chemo-enzymatic hydrolysis of LCMs. Chemical methods generate XOS with a broad degree of polymerization (DP), while enzymatic processes will be beneficial for the manufacture of food grade and pharmaceutically important XOS. Xylooligomers exert several health benefits, and therefore, have been considered to provide relief from several ailments. This review provides a brief on production, purification and structural characterization of XOS and their health benefits.

Adjuvants, Immunologic/economics , Adjuvants, Immunologic/isolation & purification , Adjuvants, Immunologic/pharmacology , Adjuvants, Immunologic/therapeutic use , Animals , Anticarcinogenic Agents/economics , Anticarcinogenic Agents/isolation & purification , Anticarcinogenic Agents/pharmacology , Anticarcinogenic Agents/therapeutic use , Antioxidants/economics , Antioxidants/isolation & purification , Antioxidants/pharmacology , Antioxidants/therapeutic use , Biomass , Carbohydrate Sequence , Chromatography/methods , Crops, Agricultural/chemistry , Crops, Agricultural/economics , Dietary Fiber/analysis , Fungal Proteins/metabolism , Gastrointestinal Tract/microbiology , Glucuronates/economics , Glucuronates/isolation & purification , Glucuronates/pharmacology , Glucuronates/therapeutic use , Humans , Hydrolysis , Lignin/analysis , Microbiota/drug effects , Molecular Sequence Data , Molecular Structure , Oligosaccharides/economics , Oligosaccharides/isolation & purification , Oligosaccharides/pharmacology , Oligosaccharides/therapeutic use , Prebiotics/economics , Waste Products/economics , Xylans/chemistry
J. pediatr. (Rio J.) ; 87(4): 292-300, jul.-ago. 2011.
Article in Portuguese | LILACS | ID: lil-598482


OBJETIVO: Avaliar o impacto do uso de probióticos e prebióticos na saúde das crianças. FONTES DOS DADOS: Foram pesquisados os bancos de dados MEDLINE e LILACS, selecionando-se artigos relevantes em inglês e francês. SÍNTESE DOS DADOS: O leite humano é rico em oligossacarídeos prebióticos e pode conter probióticos. Não existem dados sugerindo que a adição de probióticos a fórmulas para lactentes possa ser prejudicial, mas as evidências de sua eficácia são insuficientes para que seja recomendada. Visto que dados sugerem que a adição de oligossacarídeos prebióticos específicos pode reduzir infecções e atopia em lactentes saudáveis, sua adição parece razoável. Os benefícios a longo prazo dos pro e prebióticos para o sistema imunológico em desenvolvimento ainda precisam ser comprovados. Probióticos selecionados reduzem a duração da diarreia infecciosa em 1 dia, mas faltam evidências quanto à prevenção, exceto na diarreia associada a antibióticos. Alguns probióticos específicos previnem a enterocolite necrosante, e outros micro-organismos podem ser benéficos nos casos de gastrite por Helicobacter pylori e de cólica do lactente. Não há evidências suficientes para recomendar o uso de probióticos na prevenção e no tratamento da dermatite atópica. A utilização de probióticos nos casos de constipação, síndrome do intestino irritável, doença inflamatória intestinal e infecções extraintestinais requer mais estudos. CONCLUSÕES: A duração da administração, a dosagem microbiana e as espécies utilizadas necessitam de maior validação, tanto para probióticos quanto para prebióticos. Alegações de saúde injustificadas são uma grande ameaça ao conceito de pro e prebióticos.

OBJECTIVE: To evaluate the impact of probiotics and prebiotics on the health of children. SOURCES: MEDLINE and LILACS were searched for relevant English and French-language articles. SUMMARY OF THE FINDINGS: Human milk is rich in prebiotic oligosaccharides and may contain some probiotics. No data suggest that addition of probiotics to infant formula may be harmful, but evidence of its efficacy is insufficient for its recommendation. Since data suggest that addition of specific prebiotic oligosaccharides may reduce infections and atopy in healthy infants, their addition to infant formula seems reasonable. Long-term health benefits of pro- and prebiotics on the developing immune system remain to be proven. Selected probiotics reduce the duration of infectious diarrhea by 1 day, but evidence in prevention is lacking, except in antibiotic-associated diarrhea. Some specific probiotics prevent necrotizing enterocolitis, and other microorganisms may be beneficial in Helicobacter pylori gastritis and in infantile colic. Evidence is insufficient to recommend probiotics in prevention and treatment of atopic dermatitis. The use of probiotics in constipation, irritable bowel syndrome, inflammatory bowel disease, and extra-intestinal infections requires more studies. CONCLUSIONS: Duration of administration, microbial dosage, and species used need further validation for both pro- and prebiotics. Unjustified health claims are a major threat for the pro- and prebiotic concept.

Child , Humans , Infant , Diarrhea, Infantile/prevention & control , Gastroenteritis/prevention & control , Oligosaccharides , Prebiotics , Probiotics/therapeutic use , Diarrhea, Infantile/therapy , Infant Formula/chemistry , Milk, Human/chemistry , Oligosaccharides/therapeutic use , Prebiotics/adverse effects , Prebiotics/classification , Probiotics/classification
Arch. latinoam. nutr ; 59(4): 358-368, dic. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-588639


Las enfermedades gastrointestinales siguen siendo un problema de salud pública mundial. El avance de la ciencia muestra que cambios en el balance adecuado de la microflora intestinal (MI) juegan un papel crucial en la patogénesis. La evidencia apunta a que una manera de modular esta MI es a través del uso de oligosacáridos prebióticos, que estimulan el crecimiento de bacterias benéficas y que a la vez aumentan la resistencia a la invasión por patógenos. Estudios con animales indican que el consumo de carbohidratos prebióticos podría estar implicado en la prevención y tratamiento de diarreas. En infantes humanos sanos, los estudios revelan que el consumo de mezclas de prebióticas (galactooligosacáridos/fructooligosacáridos, inulina/galactooligosacáridos) disminuyen la incidencia de fiebre, de infecciones y de patógenos gastrointestinales. Lo anterior representa un gran potencial para los alimentos funcionales que los contienen, principalmente las fórmulas infantiles. Sin embargo, los estudios de prevención de diarreas mediante el suministro de prebióticos en personas con una microflora intestinal alterada no son concluyentes, sobre todo aquellos practicados en ancianos, personas con problemas crónicos de inflamación intestinal y personas con diarreas asociadas a la toma de antibióticos. Lo anterior nos indica la necesidad de estudios bioquímicos y microbiológicos más profundos en humanos de diferentes edades y condiciones de salud intestinal, a fin de determinar en que condiciones, los prebióticos tienen algún efecto sobre las infecciones.

Gastrointestinal disorders are still a main world public health problem. Scientific progress shows that and inadequate balance in intestinal microbiota (IM) plays a crucial role in its pathogenesis. Evidence indicates that one way to modulate the IM is through the use of prebiotics. These oligosaccharides stimulate the growth of benefic bacteria and increase the resistance to invading pathogens. Research using animals show that the consumption of prebiotics could be implicated in prevention and treatment of diarrhea. Studies in healthy infants also indicate that the consumption of prebiotic mixtures (galactooligosaccharides/ fructooligosaccharides, inulin/ galactooligosaccharides) decreases the incidence of fever, infections and pathogens. These results represent a great potential for functional foods that contain prebiotics, mainly the infant formulas. However, results of other clinical studies for prebiotics effects on diarrhea are not conclusive. Specially those studies that include patients with an altered IM (like the elderly), patients with chronic intestinal inflammation and with diarrhea associated to antibiotic treatments. There is a need for more biochemical and microbiological studies in humans at different ages and intestinal health conditions, in order to determine when prebiotics may effectively function on infections.

Humans , Male , Female , Gastrointestinal Diseases/prevention & control , Intestinal Diseases/prevention & control , Infection Control , Inulin/therapeutic use , Oligosaccharides/therapeutic use
Acta gastroenterol. latinoam ; 38(1): 16-25, mar. 2008. tab, graf
Article in English | LILACS | ID: lil-490476


Background/aims: functional constipation is a prevalent problem within the western population. There is evidence supporting the fact that the inclusion of pre and probiotics in the diet can favorably modify the intestinal function. The present study evaluates the effect of the consumption of Activia®, a yogurt containing 108 UFC/g of Bifidobacterium animalis (DN-173 010) and fructoligosaccharide, in women between the ages of 18 and 55 with and without functional constipation (Rome II criteria). Methods: after a stabilization and a basal period, women were randomized to receive 2 units/day of Activia or a lacteous dessert without probiotics (control) for a period of 14 days. Afterwards the groups were intercrossed for another 14 days. Results: of the 399 women who started the study, 378 were eligible for study participation. In the group of women with functional constipation (n= 266), the consumption of the symbiotic was associated with a higher bowel evacuation rate (6.1±2.7 depositions/week with Activia vs. 5.0±2.6 dep./week in the control group; P<0.01), an improvement in the quality of the stools according to the Bristol scale (3.6±1.0 vs. 3.4±1.0; P<0.01), a reduced perception of straining effort (1.9±0.8 vs. 2.2±0.9; P<0.01) and a reduced perception of pain associated with defecation (0.1±0.2 vs. 0.2±0.3; P<0.01). In the group of women without constipation (n=112) there were statistically significant variations in equal sense but of smaller magnitude, with the exception of pain which, having a very low vavaluein the basal period, did not experience changes. Conclusion: the consumption of a symbiotic yogurt by women with functional constipation showed a significant improvement in the parameters related with bowel evacuation. The use of this symbiotic food can result in a useful and safe tool for managing constipation.

Introducción/objetivos: la constipación funcional es un problema prevalente en la población occidental. Existen evidencias de que la toma de alimentos pre y probióticos puede modificar favorablemente el hábito evacuatorio intestinal. En este trabajo se estudió el efecto de la ingesta de Activia®, un yogur conteniendo 10 8 UFC/g de Bifidobacterium animalis (DN-173 010) y un fructoligosacárido en mujeres de 18 a 55 años con y sin constipación funcional (criterios de Roma II). Métodos: luego de sendos períodos de estabilización y basal fueron aleatorizadas a recibir durante 14 días 2 unidades/día de Activia o de un postre lácteo sin probiótico ni prebiótico (control). Luego los grupos fueron entrecruzados durante otros 14 días. Resultados: de las 399 mujeres que iniciaron el estudio, 378 fueron evaluables. En el grupo de constipadas (n= 266) la toma del simbiótico se asoció con una mayor frecuencia evacuatoria (6,1±2,7 dep./semana con Activia vs. 5,0±2,6 dep./semana en controles; P<0,01), mejoría en la escala de Bristol de calidad de las heces (3,6±1,0 vs. 3,4±1,0; P<0,01), menor esfuerzo evacuatorio (1,9±0,8 vs. 2,2±0,9; P<0,01) y menor proporción de dolor evacuatorio (0,1±0,2 vs. 0,2±0,3 ; P<0,01). En el grupo sin constipación se observaron variaciones estadísticamente significativas en igual sentido pero de menor magnitud, con excepción del dolor que mostró un valor basal muy bajo. Conclusión: la ingesta del yogurt prebiótico en mujeres con constipación funcional mostró una mejoría significativa de los parámetros relacionados con la evacuación intestinal. La utilización de este alimento simbiótico puede resultar una herramienta útil y segura en el manejo de la constipación.

Humans , Female , Adolescent , Adult , Middle Aged , Bifidobacterium , Constipation/diet therapy , Oligosaccharides/therapeutic use , Probiotics/therapeutic use , Yogurt , Case-Control Studies , Surveys and Questionnaires , Treatment Outcome
Rev. méd. Chile ; 135(8): 1048-1055, ago. 2007. ilus
Article in Spanish | LILACS | ID: lil-466497


Atrial fibrillation is the most common sustained arrhythmia in clinical practice and is associated to thromboembolic complications. Anticoagulation with vitamin K antagonists is clearly useful to reduce the incidence of emboli, but associated with important limitations. Therefore, there is an active search for medications that are more effective and simpler to prescribe and manage. Synthetic pentasaccharides of heparin such as idraparinux for parenteral use, showed promising results. Direct inhibitors of thrombin were also useful for the prevention of thromboembolism. However, they were withdrawn from the market due to potentially fatal adverse reactions. Other area of investigation has been the effectiveness of the combination of antiplatelet agents such as aspirin and clopidrogel. Although this combination is attractive, results of clinical trials must be awaited to have an opinion about its real usefulness. Finally, ieft atrial appendage transcatheter occlusion (PLAATO) is an effective and reasonably safe method for patients with contraindications for anticoagulation or those that continue to embolize despite well prescribed anticoagulation. The long term results of this intervention must also be awaited.

Humans , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Thromboembolism/prevention & control , Controlled Clinical Trials as Topic , Heparin/therapeutic use , Multicenter Studies as Topic , Oligosaccharides/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Thrombin/antagonists & inhibitors , Thromboembolism/etiology
Acta cir. bras ; 21(5): 315-320, Sept.-Oct. 2006. graf
Article in English, Portuguese | LILACS | ID: lil-438757


PURPOSE: To evaluate the effect of soluble fiber or fructooligosaccharide (FOS) supplementation upon trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. METHODS: 64 Wistar rats were given water, soluble fiber or FOS intragastrically during 14 days prior to colitis induction with TNBS (n=48) or rectal enema with water (n=16; control group). On the 7th or 14th day following colitis induction the rats were weighed and euthanized in order to determine the colon weight/length ratio and macroscopic and microscopic scores. RESULTS: On the 7th day following colitis induction the body weight had decreased significantly, the colon weight/length ratio had increased and macroscopic and microscopic colon lesions were observed. On the 14th day following colitis induction no difference in body weight was observed, in spite of the persistence of macroscopic and microscopic lesions and increased colon weight/length ratio. Supplementation with soluble fiber or FOS did not revert colon lesions or any of the study parameters. Supplementation with FOS, but not with fiber, was associated with increased colon weight/length ratio on the 14th day. CONCLUSION: Supplementation with soluble fiber or FOS produced no significant impact on TNBS-induced colitis in rats.

OBJETIVO: Avaliar a suplementação de fibra solúvel ou frutooligossacarídeos (FOS) na colite induzida por TNBS em ratos. MÉTODOS: Sessenta e quatro ratos Wistar receberam por gavagem água, fibra solúvel ou FOS. Após 14 dias, foram submetidos à indução de colite com TNBS. O grupo controle recebeu água por gavagem e por enema retal. Decorridos 7 ou 14 dias, após a avaliação do peso, os ratos foram sacrificados e o peso do colo, escores macroscópicos e microscópicos da lesão cólica foram aferidos. RESULTADOS: No 7° dia após indução da colite, houve uma significativa diminuição do peso dos ratos, um aumento do peso do cólon e lesão cólica macroscópica/microscópica. A suplementação com fibra ou FOS não reverteu nenhum destes parâmetros. No 14° dia após a indução da colite não foram observadas diferenças no peso dos ratos, entretanto houve uma persistência da lesão cólica macroscópica/microscópica e do aumento do peso do cólon. A suplementação com fibra ou FOS não reverteu à lesão cólica. A suplementação de FOS, mas não de fibra, aumentou o peso do colo comparado com o grupo colite no 14° dia. CONCLUSÃO: A suplementação com fibra solúvel ou com FOS não alterou a colite por TNBS em ratos.

Animals , Male , Rats , Colitis/pathology , Colon/pathology , Dietary Supplements , Dietary Fiber/therapeutic use , Oligosaccharides/therapeutic use , Administration, Oral , Administration, Rectal , Body Weight/drug effects , Colitis/chemically induced , Colitis/diet therapy , Colon/drug effects , Disease Models, Animal , Dietary Fiber/pharmacology , Enema , Organ Size , Oligosaccharides/pharmacology , Rats, Wistar , Statistics, Nonparametric , Time Factors , Trinitrobenzenesulfonic Acid/adverse effects
Rev. paul. pediatr ; 22(4): 205-211, dez. 2004. tab
Article in Portuguese | LILACS | ID: lil-412838


Objetivo: estudar a influência de um prebiótico (oligossacarídeo) acrescido ao leite em pó modificado sobre a flora intestinal de crianças. Métodos: estudo duplo-cego de crianças eutróficas com mais de 1 e menos de 4 anos de idade randomizadas por sorteio em computador a duas dietas: ingestão de leite em pó modificado com adição de prebiótico )n = 14) e leite em pó sem essa adição (n = 14). A oferta de 500 ml/dia dos leites foi feita por 21 dias, de tal maneira que a equipe de pesquisa e a família desconheciam a presença ou não do prebiótico. A análise microbiológica da flora fecal foi realizada antes e após 21 dias de tratamento pelo Laboratório Especial de microbiologia do instituto Butantan. Para a comparação estatística, empregaram-se testes não paramétricos, considerando-se significante p < 0,005. Resultados: ao início do estudo, os dois grupos foram homogêneos em relação ao número de colônias de lacto e bífidos bacilos. Aos 21 dias, o grupo com prebiótico apresentou aumento do número de colônias de lactobacilos muito próximo de significância estatística (p = 0,065) e crescimento altamente significante do número de colônias de bífidos (p = 0,0033). Na comparação entre os grupos após 21 dias de tratamento, constatou-se que o número de colônias de bífidos foi maior no grupo com prebiótico (p = 0,0212).

Humans , Infant , Child, Preschool , Child Nutrition , Double-Blind Method , Infant Nutrition , Oligosaccharides/therapeutic use
Bol. méd. Hosp. Infant. Méx ; 45(7): 437-41, jul. 1988. tab
Article in Spanish | LILACS | ID: lil-69546


Se valoró la eficacia y seguridad de una solución salina que contiene glicina y oligosacáridos, comparando los resultados con los obtenidos en un grupo tratado con la solución recomendada por la OMS. La investigación se llevó a efecto en forma ciega, seleccionando los casos de manera aleatoria entre niños que presentaban deshidratación consecutiva a un episodio de diarrea aguda. Entre los 58 enfermos tratados durante 12 horas con una y otra solución, no se observaron diferencias significativas en las valoraciones bioquímicas realizadas, ni en los cambios clínicos que ocurrieron durante el tratamiento. Se comenta acerca de la utilidad que tienen las soluciones en las que se proporciona un mayor aporte de energia

Infant , Humans , Dehydration/therapy , Fluid Therapy , Saline Solution, Hypertonic/therapeutic use , Glycine/therapeutic use , Oligosaccharides/therapeutic use
Bol. méd. Hosp. Infant. Méx ; 43(12): 755-60, dic. 1986. tab
Article in Spanish | LILACS | ID: lil-39959


Teniendo como precedente que la glicina y algunos oligosacáridos promueven la absorción del agua y el sodio, cuando se emplean en soluciones diseñadas para la hidratación por vía bucal, se diseñaron tres soluciones cuyo contenido en sales era semejante a la fórmula de la solución de la OMS, excepto por tener 80 mmol/l de sodio y haber substituido la glucosa por Maltrín 10 y/o glicina. Mediante la transfusión de las soluciones en estudio al intestino de un grupo de ratas (10 para cada solución), al cabo de 75 minutos se encontró que la solución identificada con la letra C, conteniendo una cantidad equismolar de Maltrín y glicina, era tan eficiente como la solución de la OMS para permitir la incorporación de agua y a su vez favorecía de manera aún más eficaz la absorción del sodio

Rats , Animals , Diarrhea, Infantile/therapy , Fluid Therapy , Glycine/therapeutic use , Oligosaccharides/therapeutic use , Intestinal Absorption/drug effects , Hypertonic Solutions , Sodium/metabolism , Water/metabolism